Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I5QX
|
||||
| Former ID |
DIB003697
|
||||
| Drug Name |
Etanercept
|
||||
| Synonyms |
Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Active rheumatoid arthritis [ICD9: 714; ICD10:M05, M06] | Approved | [1] | ||
| Sciatica [ICD10:M54.3-M54.4] | Phase 3 | [2], [3] | |||
| Pemphigus vulgaris; Vasculitis; Wegener's granulomatosis [ICD10:C91-C95, J45, J84.1, L80, M081, M45, M35.0, M40-M54, T86.0] | Phase 2 | [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21] | |||
| Company |
AstraZeneca
|
||||
| Target and Pathway | |||||
| Target(s) | TNF receptor | Target Info | Modulator | [2] | |
| Tumor necrosis factor | Target Info | Modulator | [22] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Cytokine-cytokine receptor interaction | |||||
| NF-kappa B signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| mTOR signaling pathway | |||||
| Apoptosis | |||||
| TGF-beta signaling pathway | |||||
| Osteoclast differentiation | |||||
| Antigen processing and presentation | |||||
| Toll-like receptor signaling pathway | |||||
| NOD-like receptor signaling pathway | |||||
| RIG-I-like receptor signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Natural killer cell mediated cytotoxicity | |||||
| T cell receptor signaling pathway | |||||
| Fc epsilon RI signaling pathway | |||||
| TNF signaling pathway | |||||
| Adipocytokine signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Type I diabetes mellitus | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Pertussis | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| African trypanosomiasis | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Hepatitis C | |||||
| Hepatitis B | |||||
| Influenza A | |||||
| HTLV-I infection | |||||
| Herpes simplex infection | |||||
| Proteoglycans in cancer | |||||
| Asthma | |||||
| Inflammatory bowel disease (IBD) | |||||
| Systemic lupus erythematosus | |||||
| Rheumatoid arthritis | |||||
| Allograft rejection | |||||
| Graft-versus-host disease | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Dilated cardiomyopathy | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| IL3 Signaling Pathway | |||||
| IL4 Signaling Pathway | |||||
| Leptin Signaling Pathway | |||||
| RANKL Signaling Pathway | |||||
| IL1 Signaling Pathway | |||||
| PANTHER Pathway | Apoptosis signaling pathway | ||||
| Wnt signaling pathway | |||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| Canonical NF-kappaB pathway | |||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Signaling events mediated by HDAC Class I | |||||
| TNF receptor signaling pathway | |||||
| Ceramide signaling pathway | |||||
| amb2 Integrin signaling | |||||
| RXR and RAR heterodimerization with other nuclear receptor | |||||
| IL23-mediated signaling events | |||||
| HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||||
| Caspase Cascade in Apoptosis | |||||
| Cellular roles of Anthrax toxin | |||||
| Downstream signaling in naï | |||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| Reactome | Transcriptional regulation of white adipocyte differentiation | ||||
| TNFR1-induced proapoptotic signaling | |||||
| Regulation of TNFR1 signaling | |||||
| TNFR1-induced NFkappaB signaling pathway | |||||
| TNFR1-mediated ceramide production | |||||
| TNFR2 non-canonical NF-kB pathway | |||||
| TNF signaling | |||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| TGF Beta Signaling Pathway | |||||
| Cytokines and Inflammatory Response | |||||
| MAPK Signaling Pathway | |||||
| EV release from cardiac cells and their functional effects | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Cardiac Hypertrophic Response | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Aryl Hydrocarbon Receptor | |||||
| Apoptosis | |||||
| Nanoparticle triggered regulated necrosis | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Adipogenesis | |||||
| Allograft Rejection | |||||
| TNF alpha Signaling Pathway | |||||
| TWEAK Signaling Pathway | |||||
| Extrinsic Pathway for Apoptosis | |||||
| Folate Metabolism | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| REF 2 | Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1-4. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6789). | ||||
| REF 4 | ClinicalTrials.gov (NCT00001901) Etanercept to Treat Wegener's Granulomatosis | ||||
| REF 5 | ClinicalTrials.gov (NCT00001954) Etanercept Therapy for Sjogren's Syndrome | ||||
| REF 6 | ClinicalTrials.gov (NCT00005007) Etanercept for Wegener's Granulomatosis | ||||
| REF 7 | ClinicalTrials.gov (NCT00006070) Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction | ||||
| REF 8 | ClinicalTrials.gov (NCT00034060) The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept | ||||
| REF 9 | ClinicalTrials.gov (NCT00063869) Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis | ||||
| REF 10 | ClinicalTrials.gov (NCT00107991) Etanercept for Treatment of Hidradenitis | ||||
| REF 11 | ClinicalTrials.gov (NCT00134368) Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo | ||||
| REF 12 | ClinicalTrials.gov (NCT00135720) Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris | ||||
| REF 13 | ClinicalTrials.gov (NCT00141713) The Use of Etanercept (Enbrel) in the Treatment of Acute Graft-Versus-Host Disease | ||||
| REF 14 | ClinicalTrials.gov (NCT00141726) Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant | ||||
| REF 15 | ClinicalTrials.gov (NCT00141739) Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) | ||||
| REF 16 | ClinicalTrials.gov (NCT00141791) Study Evaluating Etanercept in Moderate to Severe Asthma | ||||
| REF 17 | ClinicalTrials.gov (NCT00509600) Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | ||||
| REF 18 | ClinicalTrials.gov (NCT01289730) Etanercept (Enbrel) in Undifferentiated Spondyloarthritis | ||||
| REF 19 | ClinicalTrials.gov (NCT01289743) Etanercept (Enbrel) in Ankylosing Spondylitis | ||||
| REF 20 | ClinicalTrials.gov (NCT01730495) Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome | ||||
| REF 21 | ClinicalTrials.gov (NCT02656082) Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus | ||||
| REF 22 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.